Brought to you by 
Naurex grosses $38mm in Series B round led by Baxter Ventures; adds $25mm
04 Jun 2021
Executive Summary
First-time investor Baxter Ventures has led a $38mm Series B financing for Naurex Inc. (developing CNS compounds that safely modulate the NMDA receptor). Another new backer Savitr Capital participated along with returning shareholders Adams Street Partners, Latterell Venture Partners, Genesys Capital, PathoCapital, Druid BioVentures, Northwestern University, H. Lundbeck AS, Takeda Ventures, Shire PLC, and private investors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Naurex grosses $38mm in Series B round led by Baxter Ventures; adds $25mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice